Experimental drug could help reduce brain damage, improve motor skills after stroke
Ribbon structure of the drug 3K3A-APC, which researchers hope will help reduce brain damage in stroke victims. Credit: ZZ Biotech
(Medical Xpress)—A University of Arizona professor is overseeing the manufacture of an experimental drug that could help reduce brain damage after a stroke.
The drug, known as 3K3A-APC, currently is undergoing clinical trials in Europe to determine its safety in humans after proving effective in animal models at reducing brain damage and improving motor skills after a stroke when given in combination with another commonly used stroke therapy.
Thomas Davis, professor of pharmacology in the UA College of Medicine, was chosen to direct the manufacture of the drug for human trials after co-authoring a recent paper in the journal Stroke that pointed to the drug's effectiveness in rats and mice when used in conjunction with a clot-busting therapy known as tissue plasminogen activator, or tPA.
While tPA is commonly given to sufferers of ischemic stroke, which results from an obstruction in a blood vessel supplying blood to the brain, the therapy poses significant challenges when administered alone, including a limited treatment window, Davis said.
"It has to be given within the first three to four and a half hours of the stroke," Davis said. "It only works in 10 percent of the patients, and it causes bleeding, so tPA alone isn't that effective."
Researchers now have found that 3K3A-APC, with its cell protective properties, may be effective in extending the treatment window for tPA while protecting against programmed cell death in the brain, which occurs when cellular signals convince brain cells to kill themselves following a stroke. When tested in rodents, the combination therapy reduced brain damage by more than half, eliminated tPA-induced bleeding and significantly improved motor abilities.
The drug 3K3A-APC initially was created by a team of scientists at the Scripps Research Institute and the University of Southern California, led by John Griffin, professor at the Scripps Research Institute, and Dr. Berislav V. Zlokovic, director of the Neurogenic Institute at USC's Keck School of Medicine. It was further developed by Houston-based biotech company ZZ Biotech, for which Davis serves as a consultant and member of the scientific board of directors.
Davis worked closely with Griffin, Zlokovic and other collaborators to develop proper manufacturing procedures for the drug, which is being produced under Davis' direction by ZZ Biotech's contracted manufacturer, Laureate Biopharmaceuticals, in New Jersey.
The drug 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C, or APC, which helps regulate blood clots and inflammation in the body.
Previous research on naturally occurring APC, conducted by Griffin and Zlokovic, pointed to the protein's ability to prevent programmed cell death in the brain. However, APC's natural blood-thinning properties posed a problem when considered as a treatment for stroke, since it might induce bleeding in the brain.
To address that problem, Griffin's hematology lab worked to develop an engineered variant of APC with fewer anticoagulant properties, and thus 3K3A-APC was born.
Davis was chosen to lead the production of the drug because of his extensive drug manufacturing experience and connection to ZZ Biotech.
Prior to joining the UA College of Medicine in 1980, Davis worked as a chemist for Abbot Pharmaceutical Co. Considered a premier investigator in the field of blood brain barrier research, Davis is widely regarded for changing the way drugs are designed and manufactured by pharmaceutical companies for brain delivery.
So far, no side effects have been shown in the initial clinical trials of 3K3A-APC in normal human subjects, Davis said, adding that he is prepared to manufacture more of the drug for future trials. "Starting next January, it will go into phase two clinical trials in stroke patients as an adjuvant therapy, together with tPA."
Journal reference: Stroke
Provided by University of Arizona
- Experimental drug may extend therapeutic window for stroke Jul 17, 2012 | not rated yet | 0
- Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech Aug 08, 2012 | not rated yet | 0
- Clot-busting drug safe for stroke patients taking blood thinner May 10, 2012 | not rated yet | 0
- Hypothermia protects the brain against damage during stroke Mar 06, 2012 | not rated yet | 0
- Leukemia drug could save lives of stroke patients Jun 22, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
New research from the University of Southampton has shown that blind and visually impaired people have the potential to use echolocation, similar to that used by bats and dolphins, to determine the location of an object.
Medical research 1 hour ago | not rated yet | 1 |
A novel vaccine study from South Dakota State University (SDSU) will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference ...
Medical research 2 hours ago | not rated yet | 0
Every 20 seconds, a limb is lost as a consequence of diabetic foot ulcer that does not heal. To date, medical solutions that can change this situation are very limited. In his doctoral thesis Yue Shen from the Industrial ...
Medical research 6 hours ago | 5 / 5 (1) | 0
When tumours metastasise, they can block lymphatic vessels, as researchers from ETH Zurich have discovered using a new method. The lymphatic fluid subsequently has to find a new path through the tissue. Such ...
Medical research 6 hours ago | not rated yet | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
Medical research May 19, 2013 | 5 / 5 (3) | 0 |
New research suggests that for some hospitalized ICU patients on mechanical ventilators, using headphones to listen to their favorite types of music could lower anxiety and reduce their need for sedative medications.
8 minutes ago | not rated yet | 0 |
A small, easily implantable device called the Lung Volume Reduction Coil (LVRC) may play a key role in the treatment of two types of emphysema, according to a study conducted in Europe. Results of the study indicate the beneficial ...
8 minutes ago | not rated yet | 0
The early (within 24 hours of intensive care unit [ICU] admission) provision of intravenous nutrition among critically ill patients with contraindications (a condition that makes a particular procedure potentially inadvisable) ...
8 minutes ago | not rated yet | 0
Having a nighttime critical care physician in the ICU doesn't improve patient outcomes, research finds
With little evidence to guide them, many hospital intensive care units (ICUs) have been employing critical care physicians at night with the notion it would improve patients' outcomes. However, new results from a one-year ...
8 minutes ago | not rated yet | 0
(HealthDay)—Vitamin D supplements may help those with Crohn's disease overcome the fatigue and decreased muscle strength associated with the inflammatory bowel disease, according to new research.
18 minutes ago | not rated yet | 0